Bayer-Ó³»´«Ã½ Collaboration in Cardiovascular Disease
While a majority of cardiovascular disease can be associated with lifestyle factors such as tobacco use, diet, and level of physical activity, risk genes can influence the predisposition to cardiovascular disease, its age of onset, and its severity. In 2015, the Ó³»´«Ã½ expanded its ongoing collaboration with Bayer to include cardiovascular genomics, an emerging field of cardiology that uses genomic information to characterize disease risk and identify new therapeutic targets for drug discovery. The effort combines Bayer’s expertise in cardiovascular therapeutics with Ó³»´«Ã½â€™s deep knowledge of genomics and biology. The goal is to leverage insights from human genetics to help create new cardiovascular therapies.
